Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aprea Therapeutics Inc 3805 Old Easton Road DOYLESTOWN PA 18902 USA

www.aprea.com Employees: 7 P: 617-463-9385

Description:

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes, acute myeloid leukemia as well as additional hematologic and solid tumor malignancies. Aprea Therapeutics Inc. is based in Boston, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 16,196
Enterprise Value, $K -5,414
Shares Outstanding, K 5,435
Annual Sales, $ 580 K
Annual Net Income, $ -14,290 K
Last Quarter Sales, $ 350 K
Last Quarter Net Income, $ -3,780 K
EBIT, $ -14,770 K
EBITDA, $ -14,760 K
60-Month Beta 0.97
% of Insider Shareholders 12.80%
% of Institutional Shareholders 34.19%
Float, K 4,739
% Float 87.20%
Short Volume Ratio 0.45

Growth:

1-Year Return -20.95%
3-Year Return -96.41%
5-Year Return -99.41%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.64 on 11/07/24
Next Earnings Date 11/14/24
Earnings Per Share ttm -2.81
EPS Growth vs. Prev Qtr -10.34%
EPS Growth vs. Prev Year 25.58%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 02/13/23

APRE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -57.86%
Return-on-Assets % -47.94%
Profit Margin % -2,463.79%
Debt/Equity 0.00
Price/Sales 30.30
Price/Cash Flow N/A
Price/Book 0.80
Book Value/Share 4.04
Interest Coverage -0.70
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar